Vidalista 20 mg (Tadalafil 20 mg tablet)

1. Description

Vidalista 20 mg is a brand formulation whose active ingredient is tadalafil 20 mg. Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor used primarily for the treatment of erectile dysfunction (ED). It may also be used in other indications for which tadalafil is approved or studied (for example daily low‑dose tadalafil for ED and benign prostatic hyperplasia), but the 20 mg strength is most commonly an as‑needed dose for ED.

Key clinical points

• Indication: erectile dysfunction (on‑demand use). Tadalafil is also approved in other formulations/doses for daily therapy of ED and for some lower urinary tract symptoms associated with BPH; a separate formulation (Adcirca) is used for pulmonary arterial hypertension.
• Onset: effects can begin as early as 30 minutes in some men; typical onset 30 minutes–2 hours.
• Duration: prolonged activity compared with other PDE5 inhibitors — clinically meaningful effect may last up to ~36 hours after a single dose.
• Typical tablet strengths available: 2.5 mg, 5 mg, 10 mg, 20 mg (Vidalista 20 mg corresponds to tadalafil 20 mg).

2. How does Vidalista 20mg work?

• Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in the smooth muscle of the corpus cavernosum.
• Sexual stimulation triggers release of nitric oxide (NO) in the corpus cavernosum → increased cGMP → smooth muscle relaxation → increased blood flow into the penis producing erection.
• By inhibiting PDE5, tadalafil prolongs the action of cGMP, facilitating erection when sexual stimulation is present.
• Tadalafil also has vasodilatory effects on other vascular beds (which underlies some adverse effects and other therapeutic uses).

3. Dosage

General principles — always follow a prescriber’s instructions. The following are typical adult dosing approaches used in clinical practice:

A. On‑demand dosing (most common with 20 mg tablets)

• Typical starting dose: 10 mg taken prior to anticipated sexual activity.
• Based on efficacy and tolerability, dose may be increased to 20 mg or decreased to 5 mg.
• Timing: take at least 30 minutes before sexual activity; some patients take it 1–2 hours before. Sexual stimulation is still required.
• Frequency: do not take more than one dose within a 24‑hour period. The maximum recommended single dose for on‑demand use is 20 mg within 24 hours.

B. Daily dosing (different clinical use and lower strengths)

• For continuous daily use (e.g., daily treatment of ED or BPH symptoms), typical doses are 2.5–5 mg once daily taken at the same time each day. The 20 mg dose is not used for daily therapy.

C. Special populations / dose adjustment (general guidance)

• Elderly: no specific dose adjustment solely for age is universally required, but many clinicians start with a lower dose (e.g., 5–10 mg) to assess tolerability.
• Renal impairment: reduced renal function may increase tadalafil exposure. For moderate-to-severe renal impairment, clinicians often prescribe a lower starting dose and monitor; severe renal impairment requires individualized dosing and prescriber guidance.
• Hepatic impairment: moderate or severe hepatic impairment can increase exposure; dose adjustments and caution are advised — severe hepatic impairment may be a contraindication or require specialist advice.
• Concomitant medications: strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole) can increase tadalafil levels — a lower dose or altered dosing interval may be recommended. Strong CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) can reduce tadalafil efficacy.

D. Missed dose / overdose

• Missed dose (daily regimen): take the missed dose when remembered; do not double the next dose.
• Overdose: seek immediate medical attention. Symptoms may include severe dizziness, fainting, chest pain, prolonged erection (priapism), abnormal heartbeat, or severe hypotension.

Always consult a prescriber for individualized dosing — the above are general guidelines only.

4. Side effects

Most side effects are dose‑related and reflect vasodilation or PDE5 inhibition in non‑target tissues.

A. Common (generally mild to moderate)

• Headache
• Flushing
• Dyspepsia (indigestion)
• Nasal congestion or rhinitis
• Back pain and myalgia (can occur 12–24 hours after dosing)
• Dizziness

B. Less common / important clinically

• Visual disturbances (e.g., changes in color vision, blurred vision)
• Orthostatic hypotension (lightheadedness when standing)
• Palpitations

C. Rare but serious (require immediate medical attention)

• Priapism: painful erection lasting >4 hours — this is a urological emergency; immediate medical care is required to prevent permanent damage.
• Nonarteritic anterior ischemic optic neuropathy (NAION): sudden decrease or loss of vision in one or both eyes — stop the drug and seek urgent ophthalmic evaluation.
• Sudden hearing loss or decreased hearing, sometimes with tinnitus and dizziness — seek urgent medical attention.
• Severe hypotension, particularly when combined with nitrates or in susceptible cardiovascular patients.
• Severe allergic reactions (rare): rash, swelling, difficulty breathing.

D. Contraindications / important interactions that increase risk

• Concomitant use with nitrates (e.g., nitroglycerin, isosorbide mononitrate) or nitric oxide donors — absolute contraindication due to risk of life‑threatening hypotension.
• Concomitant use with riociguat (stimulator of soluble guanylate cyclase) — contraindicated.
• Use with alpha‑blockers: may cause symptomatic hypotension; if combined, start at a low dose and monitor blood pressure closely (managed by a clinician).
• Strong CYP3A4 inhibitors increase tadalafil levels and may increase side-effect risk; dose adjustments or avoidance may be necessary.

E. What to do if serious symptoms occur

• Erection >4 hours: go to emergency department or urgent care immediately.
• Sudden vision or hearing loss, chest pain, lightheadedness: seek immediate medical attention.

5. Storage

• Store Vidalista (tadalafil tablets) at controlled room temperature, typically 20–25 °C (68–77 °F). Short excursions permitted (consult product labeling for allowed ranges).
• Keep in original packaging to protect from moisture and light.
• Protect from excessive heat and humidity (avoid bathroom storage).
• Keep out of reach of children and pets.
• Dispose of unused medication per local regulations or take‑back programs.

Important clinical notes and precautions

• Before starting tadalafil, clinicians screen for cardiovascular risk associated with sexual activity and review current medications for drug interactions (especially nitrates and strong CYP3A4 inhibitors).
• Inform your prescriber about heart disease, recent stroke or myocardial infarction, low blood pressure, severe liver disease, kidney disease, retinitis pigmentosa, or any conditions predisposing to priapism.
• Tadalafil is for use in males with erectile dysfunction; safety and effectiveness in women and children for ED are not established.
• This guide is educational and not a substitute for professional medical advice. Dosing and treatment decisions should be made jointly with a qualified prescriber who can consider individual health status and concomitant medications.